Cargando…
Dual Fatty Acid Synthase and HER2 Signaling Blockade Shows Marked Antitumor Activity against Breast Cancer Models Resistant to Anti-HER2 Drugs
Blocking the enzyme Fatty Acid Synthase (FASN) leads to apoptosis of HER2-positive breast carcinoma cells. The hypothesis is that blocking FASN, in combination with anti-HER2 signaling agents, would be an effective antitumor strategy in preclinical HER2+ breast cancer models of trastuzumab and lapat...
Autores principales: | Blancafort, Adriana, Giró-Perafita, Ariadna, Oliveras, Glòria, Palomeras, Sònia, Turrado, Carlos, Campuzano, Òscar, Carrión-Salip, Dolors, Massaguer, Anna, Brugada, Ramon, Palafox, Marta, Gómez-Miragaya, Jorge, González-Suárez, Eva, Puig, Teresa |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4479882/ https://www.ncbi.nlm.nih.gov/pubmed/26107737 http://dx.doi.org/10.1371/journal.pone.0131241 |
Ejemplares similares
-
Fatty acid synthase expression and its association with clinico-histopathological features in triple-negative breast cancer
por: Giró-Perafita, Ariadna, et al.
Publicado: (2017) -
A novel inhibitor of fatty acid synthase shows activity against HER2+ breast cancer xenografts and is active in anti-HER2 drug-resistant cell lines
por: Puig, Teresa, et al.
Publicado: (2011) -
Circulating fatty acid synthase: an exploratory biomarker to predict efficacy of the dual HER1/HER2 tyrosine kinase inhibitor lapatinib
por: Oliveras-Ferraros, Cristina, et al.
Publicado: (2011) -
RANK signaling increases after anti-HER2 therapy contributing to the emergence of resistance in HER2-positive breast cancer
por: Sanz-Moreno, Adrián, et al.
Publicado: (2021) -
EGCG-Derivative G28 Shows High Efficacy Inhibiting the Mammosphere-Forming Capacity of Sensitive and Resistant TNBC Models
por: Giró-Perafita, Ariadna, et al.
Publicado: (2019)